Sun Exposure Behaviors of Patients With Moderate‐to‐Severe Psoriasis: Results From the French PSOBIOTEQ Cohort
ABSTRACT Background Tanning addiction is a behavioral addiction characterized by an irrepressible desire for sun or ultraviolet light exposure. It is thought to affect 10% to 25% of the population. Objectives This study aimed to estimate the prevalence of this behavior in patients with moderate‐to‐severe psoriasis and identify associated factors. Methods A cross‐sectional study of baseline data from patients included in the PsoBioTeq cohort between 2012 and 2022. Tanning addiction was approximated by patient‐reported excessive sun exposure (ESE), defined by the response “I try to expose myself to the sun as often as possible” to a registry question on current behavior. Factors associated with ESE including clinical characteristics, psoriasis and medical history, and previous treatments were also analyzed. Results Among 3705 patients included in the analysis, 636 (17.2%) reported ESE. In multivariate analysis, being younger (OR 0.97, 95% CI [0.96; 0.97]) and female (OR 1.52, 95% CI [1.20; 1.93]), and having a normal weight (OR 0.57, 95% CI [0.42; 0.77]), intermediate skin phenotype (OR 1.80, 95% CI [1.36; 2.38]), and history of phototherapy (OR 1.53, 95% CI [1.19; 1.96]) were associated with a higher ESE risk, whereas previous ustekinumab treatment (OR 0.40, 95% CI [0.19; 0.84]) was associated with a lower ESE risk. Conclusions The prevalence of ESE in patients with psoriasis was 17% and revealed demographic factors that may help to identify the patient population most risk of ESE behavior. Education about photoprotection and optimal rapid control of psoriasis may be particularly important for this population.
Authors
- N. Beneton
- M. Beylot‐Barry (ORCID: https://orcid.org/0000-0001-6150-1229)
- E. Mahé (ORCID: https://orcid.org/0000-0001-5780-1827)
- C. Paul
- F. Tubach
- H. Bachelez
- M.‐A. Richard (ORCID: https://orcid.org/0000-0002-0870-9132)
- M. Viguier
- Alain Dupuy (ORCID: https://orcid.org/0000-0003-3212-7455)
- R. Curmin (ORCID: https://orcid.org/0000-0002-1272-5813)
- P. Joly (ORCID: https://orcid.org/0000-0002-5734-0255)
- D. Jullien (ORCID: https://orcid.org/0000-0002-2995-7928)
- É. Sbidian (ORCID: https://orcid.org/0000-0002-1267-5270)
- O. Chosidow (ORCID: https://orcid.org/0000-0002-8400-4310)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Délégation Paris 7 (FR)
- Université Paris-Est Créteil (FR)
- Université Paris Cité (FR)
- Aix-Marseille Université (FR)
- Sorbonne Université (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Sorbonne Paris Cité (FR)
- Hospices Civils de Lyon (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpital Pontchaillou (FR)
- Centre Hospitalier du Mans (FR)
- Hôpital Robert-Debré (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Centre Hospitalier Victor Dupouy (FR)
- Hôpital Saint-Louis (FR)
- Institut des Maladies Génétiques Imagine (FR)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- JEADV Clinical Practice
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1002/jvc2.70029
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Celgene
- MSD France
- Société Française de Dermatologie et de Pathologie Sexuellement Transmissible
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
- Assistance publique-Hôpitaux de Paris
- LEO Pharma
- Novartis Pharma